Excellent effects and possible mechanisms of action of a new antibody –drug conjugate against EGFR-positive triple-negative breast cancer
ConclusionsLR004-VC-MMAE showed effective antitumor activity by inhibiting the activation of EGFR signaling and the expression of cancer stemness marker genes. It might be a promising therapeutic candidate and provides a potential therapeutic avenue for the treatment of EGFR-positive TNBC.
Source: Military Medical Research - Category: International Medicine & Public Health Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | International Medicine & Public Health | Laboratory Medicine | Research | Stem Cell Therapy | Stem Cells | Study